ISR Share Price Performance
Recent ISR News & Updates
No updates
ISR Immune System Regulation Holding AB (publ) Key Details
Last Reported Earnings
Dec 31, 2022
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -3.09
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- -0.6%
ISR Immune System Regulation Holding AB (publ) Competitors
About ISR
- Founded
- 2007
- Employees
- 5
- CEO
- WebsiteView website
ISR Immune System Regulation Holding AB (publ) develops immunostimulatory drugs to treat chronic infectious diseases and cancer in Sweden. Its product pipeline includes Covid-19 vaccine, hepatitis B (HBV), human immunodeficiency virus (HIV), and oncology drugs. The company was founded in 2007 and is headquartered in Solna, Sweden.
Swedish Market Performance
- 7 Days: -0.3%
- 3 Months: 5.1%
- 1 Year: -2.9%
- Year to Date: 1.1%
Over the last 7 days, the market has risen 1.9%, driven by gains of 2.1% in the Industrials sector. The market has been flat overall in the last year. Looking forward, earnings are forecast to grow by 17% annually. Market details ›
Companies across the globe are beginning to pay attention to agentic AI. It’s also a term you’re likely to hear a lot during earnings season. In fact, it came up 26 times during...
Continue reading